Stockscreener 앱 받기
4.83
0.62%
-0.03
시간 외 거래:
4.82
-0.010
-0.21%
전일 마감가:
$4.86
열려 있는:
$4.78
하루 거래량:
310.01K
Relative Volume:
0.53
시가총액:
$157.39M
수익:
$2.00M
순이익/손실:
$-51.04M
주가수익비율:
-3.0589
EPS:
-1.579
순현금흐름:
$-45.65M
1주 성능:
-9.55%
1개월 성능:
-10.22%
6개월 성능:
-25.92%
1년 성능:
+25.45%
1일 변동 폭
$4.64
$4.8873
1주일 범위
$4.64
$5.44
52주 변동 폭
$1.73
$11.41
Sagimet Biosciences Inc Stock (SGMT) Company Profile
명칭
Sagimet Biosciences Inc
전화
(650) 561-8600
주소
155 BOVET RD., SUITE 303, SAN MATEO
Compare SGMT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
4.83 | 158.36M | 2.00M | -51.04M | -45.65M | -1.579 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-03 | 개시 | Guggenheim | Buy |
| 2026-01-28 | 개시 | Barclays | Equal Weight |
| 2025-08-11 | 개시 | Wedbush | Outperform |
| 2025-08-07 | 재개 | H.C. Wainwright | Buy |
| 2025-07-24 | 개시 | Canaccord Genuity | Buy |
| 2024-12-06 | 개시 | Oppenheimer | Outperform |
| 2024-11-12 | 개시 | UBS | Buy |
| 2024-06-28 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-05-02 | 개시 | H.C. Wainwright | Buy |
| 2024-03-25 | 개시 | Leerink Partners | Outperform |
| 2023-08-08 | 개시 | Goldman | Buy |
| 2023-08-08 | 개시 | JMP Securities | Mkt Outperform |
| 2023-08-08 | 개시 | Piper Sandler | Overweight |
| 2023-08-08 | 개시 | TD Cowen | Outperform |
모두보기
Sagimet Biosciences Inc 주식(SGMT)의 최신 뉴스
Total debt per share of Sagimet Biosciences Inc. Class A – DUS:0O2 - TradingView
HC Wainwright Has Negative Outlook for SGMT FY2027 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Sagimet Biosciences, Inc. Class A (SGMT) and Bristol-Myers Squibb (BMY) - The Globe and Mail
Sagimet Biosciences (NASDAQ:SGMT) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Q1 Earnings Forecast for SGMT Issued By HC Wainwright - MarketBeat
Citizens reiterates Sagimet Biosciences stock rating on MASH progress - Investing.com UK
Citizens reiterates Sagimet Biosciences stock rating on MASH progress By Investing.com - Investing.com Nigeria
Sagimet: Advancing FASN Inhibitor Pipeline and Solid Cash Position Support Buy Rating and $26 Target - TipRanks
Sagimet: Underappreciated, De-Risked Pipeline with Near-Term Milestones Supports Buy Rating - TipRanks
Sagimet Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Sagimet Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Oppenheimer reiterates Sagimet stock rating on MASH trial progress By Investing.com - Investing.com India
Oppenheimer reiterates Sagimet stock rating on MASH trial progress - Investing.com
Sagimet Biosciences Reports 2025 Financial Results, Advances MASH and Acne Clinical Programs with Denifanstat and Resmetirom Combination 14 - Minichart
Sagimet Biosciences (NASDAQ:SGMT) Receives Buy Rating from HC Wainwright - MarketBeat
Sagimet: Undervalued MASH and Acne Pipeline with Best-in-Class Combination Potential Supports Buy Rating - TipRanks
Sagimet Biosciences Advances FASN Inhibitor Pipeline with Positive Phase 3 Results for Denifanstat in Acne and MASH Clinical Trials - Minichart
Sagimet Biosciences (NASDAQ:SGMT) Posts Quarterly Earnings Results, Beats Expectations By $0.14 EPS - MarketBeat
Sagimet Biosciences Reports 2025 Results, Highlights Clinical Progress - TipRanks
MASH and acne trial gains highlight Sagimet (NASDAQ: SGMT) 2025 update - Stock Titan
Sagimet Biosciences Q4 net loss narrows as R&D expenses fall - TradingView
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates - The Manila Times
SGMT: Positive clinical progress in MASH and acne, with $113.1M cash and $51.0M net loss in 2025 - TradingView
Sagimet 10-K: Net Loss $51.0M, EPS $(1.58) - TradingView
Acne drug filing in China, new liver trial planned by Sagimet - Stock Titan
Sagimet Biosciences Inc expected to post a loss of 41 cents a shareEarnings Preview - TradingView
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Sagimet Biosciences (SGMT) Projected to Post Earnings on Wednesday - MarketBeat
Sagimet Biosciences Highlights Denifanstat MASH Data, Combo Plans at Oppenheimer Healthcare Conf. - Defense World
Bull Bear: How does Sagimet Biosciences Inc score in quality rankings2025 Macro Impact & Consistent Profit Alerts - baoquankhu1.vn
SGMT Should I Buy - Intellectia AI
SGMT: Lead FASN inhibitor advances in MASH and acne, with pivotal trials and regulatory milestones ahead - TradingView
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences - The Manila Times
Sagimet Biosciences to Participate in Upcoming Investor Conferences in March 2026 - Quiver Quantitative
Biotech Sagimet lines up three March investor conferences - Stock Titan
SGMT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
SGMTSagimet Biosciences Inc. Latest Stock News & Market Updates - Stock Titan
Sagimet (NASDAQ: SGMT) CMO receives 88,000-share option and 44,000 RSUs - Stock Titan
Sagimet Biosciences (SGMT) CFO awarded 88,000 options and 44,000 RSUs - Stock Titan
What is the long term forecast for Sagimet Biosciences Inc. stockChart Signals & Short-Term Swing Trade Alerts - mfd.ru
Can Sagimet Biosciences Inc. continue delivering strong returnsTrade Volume Report & Smart Money Movement Alerts - mfd.ru
Sagimet (SGMT) CEO granted 256k options and 128k RSUs in Form 4 - Stock Titan
Growth Value: Is Sagimet Biosciences Inc in a consolidation phaseJuly 2025 Retail & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Sagimet Biosciences (NASDAQ:SGMT) vs. AC Immune (NASDAQ:ACIU) Financial Survey - Defense World
Don't Ignore The Insider Selling In Sagimet Biosciences - simplywall.st
Sagimet Biosciences Showcases FASN Strategy, MASH Phase II Timeline and Acne Data at Guggenheim Conference - MarketBeat
Will Sagimet Biosciences Inc. face regulatory challengesWeekly Loss Report & Safe Entry Momentum Stock Tips - mfd.ru
Viking Therapeutics, Genfit, Sagimet jump as Novo to buy Akero - MSN
Top Sagimet Executives Quietly Unload Shares in Coordinated Insider Move - TipRanks
David Happel Sells 12,101 Shares of Sagimet Biosciences (NASDAQ:SGMT) Stock - MarketBeat
Sagimet Biosciences Inc (SGMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):